{'52WeekChange': 0.41486073,
 'SandP52WeekChange': None,
 'address1': '4505 Emperor Boulevard',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.47,
 'askSize': 2200,
 'averageDailyVolume10Day': 5601250,
 'averageVolume': 9506330,
 'averageVolume10days': 5601250,
 'beta': 2.87675,
 'beta3Year': None,
 'bid': 4.44,
 'bidSize': 4000,
 'bookValue': 0.024,
 'category': None,
 'circulatingSupply': None,
 'city': 'Durham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.54,
 'dayLow': 4.33,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.969,
 'enterpriseToRevenue': 13.787,
 'enterpriseValue': 658608832,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '919-859-1314',
 'fiftyDayAverage': 4.696857,
 'fiftyTwoWeekHigh': 6.29,
 'fiftyTwoWeekLow': 1.38,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 135457470,
 'forwardEps': -0.76,
 'forwardPE': -5.8552628,
 'fromCurrency': None,
 'fullTimeEmployees': 140,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00955,
 'heldPercentInstitutions': 0.90202004,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/biocryst.com',
 'longBusinessSummary': 'BioCryst Pharmaceuticals, Inc., a biotechnology '
                        'company, discovers oral and small-molecule medicines. '
                        'The company markets peramivir injection, an '
                        'intravenous neuraminidase inhibitor, for the '
                        'treatment of acute uncomplicated influenza under the '
                        'RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and '
                        'Mundesine, an oral purine nucleoside phosphorylase '
                        'inhibitor for peripheral T-cell lymphoma. It is also '
                        'developing BCX7353, an oral serine protease inhibitor '
                        'and oral dose formulation that is in Phase III '
                        'clinical trials to treat hereditary angioedema; '
                        'BCX9930, an oral factor D inhibitor, which is in '
                        'Phase I clinical trials for mediated diseases; '
                        'BCX9250, an oral activin receptor-like kinase-2 '
                        'inhibitors that is in preclinical trials to treat '
                        'fibrodysplasia ossificans progressive; and '
                        'Galidesivir, an RNA dependent-RNA polymerase '
                        'inhibitor, which is in Phase I clinical trials to '
                        'treat various RNA viruses, including Marburg, Yellow '
                        'Fever, Ebola, and Zika. The company has '
                        'collaborations and in-license relationships with U.S. '
                        'Department of Health and Human Services; National '
                        'Institute of Allergy and Infectious Diseases; Seqirus '
                        'UK Limited; Shionogi & Co., Ltd.; Green Cross '
                        'Corporation; Mundipharma International Holdings '
                        'Limited; and The University of Alabama at Birmingham, '
                        'as well as Albert Einstein College of Medicine of '
                        'Yeshiva University and Industrial Research, Ltd. '
                        'BioCryst Pharmaceuticals, Inc. was founded in 1986 '
                        'and is headquartered in Durham, North Carolina.',
 'longName': 'BioCryst Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 784984384,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_25594',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -115442000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.494,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.26,
 'phone': '919-859-1302',
 'previousClose': 4.57,
 'priceHint': 4,
 'priceToBook': 185.41666,
 'priceToSalesTrailing12Months': 16.432238,
 'profitMargins': -2.41657,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.54,
 'regularMarketDayLow': 4.33,
 'regularMarketOpen': 4.494,
 'regularMarketPreviousClose': 4.57,
 'regularMarketPrice': 4.494,
 'regularMarketVolume': 4403218,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 176400992,
 'sharesPercentSharesOut': 0.18200001,
 'sharesShort': 32096579,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 18431728,
 'shortName': 'BioCryst Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.19559999,
 'shortRatio': 4.15,
 'startDate': None,
 'state': 'NC',
 'strikePrice': None,
 'symbol': 'BCRX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.912,
 'twoHundredDayAverage': 3.5844605,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '96bb866f-1671-37bb-8fb4-22c003011687',
 'volume': 4403218,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.biocryst.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '27703'}